• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

HPV vaccine not associated with Multiple Sclerosis

byJeffrey CohenandPriyanka Vedak
January 7, 2015
in Chronic Disease, Infectious Disease, Neurology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This cohort study demonstrated no increased risk of multiple sclerosis (MS) among girls and women who received the quadrivalent human papillomavirus (HPV) vaccine in Denmark and Sweden.

2. This cohort study additionally demonstrated no increased risk of other, non-MS demyelinating diseases of the central nervous system among girls and women who received the quadrivalent human papillomavirus (HPV) vaccine in Denmark and Sweden.

Evidence Rating Level: 2 (Good)

Study Rundown: The quadrivalent human papillomavirus (HPV) vaccine was introduced in 2006 and has resulted in the widespread vaccination of girls and young women worldwide. However, one safety concern that has surfaced since 2006 is a potential association between HPV vaccination and demyelinating diseases of the central nervous system, such as multiple sclerosis (MS). This study analyzed vaccinated Swedish and Danish females between 10 and 44 years of age to explore an association between vaccination and MS and other demyelinating diseases (i.e. optic neuritis, transverse myelitis, acute disseminated encephalomyelitis, and neuromyelitis optica). A total of 3,978,271 individuals were included in the MS analysis, and no association between vaccination and MS was observed. There was also no association between vaccination and other demyelinating disorders. Strengths of this study include the use of carefully managed vaccination record databases and the large number of individuals included in the study. Additionally, this study included all vaccination data from two European countries. One weakness of the study is the lack of family history or other demographic data to control for potential confounders. Additionally, outcomes were based on ICD-10 codes, which may not have correctly identified all cases of MS and other demyelinating diseases. Overall, however, this study demonstrates compelling evidence against an association between quadrivalent HPV vaccination and MS or other demyelinating diseases.

Click to read the study, published today in JAMA

Relevant Reading: Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.

RELATED REPORTS

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

In-Depth [population-based cohort study]: This study explored the association between quadrivalent HPV vaccination and MS and other demyelinating diseases among 3,978,271 Danish and Swedish females between the ages of 10 and 44 years and followed for 21,332,622 total person-years. MS and other demyelinating diseases were identified based on ICD-10 billing codes during a risk period defined as 2 years following each HPV vaccination dose. During these risk periods there were 73 cases of MS and 90 cases of other demyelinating diseases noted. No association between vaccination and MS was observed (adjusted RR 0.90; 95% CI 0.70-1.15). There was also no association between vaccination and other demyelinating diseases (adjusted RR 1.00; 95%CI 0.80-1.26). Additional analyses by age, country, and time from vaccination also showed no association between vaccination and MS or other demyelinating diseases.

More from this author: Ambulances equipped for thrombolysis allow for more rapid stroke treatment, Stem cell transplant may be effective in sickle cell disease, Frozen fecal transplant effective for Clostridium difficile infection, Adding sargramostim to ipilimumab may improve survival in advanced melanoma, No change in health or education outcomes following implementation of duty-hour restrictions

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: hpv vaccinemultiple sclerosis
Previous Post

Bariatric surgery linked to decreased all-cause mortality

Next Post

Criminal behavior more associated with frontotemporal dementia than Alzheimer disease

RelatedReports

Chronic Disease

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

June 2, 2025
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

June 5, 2025
#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis
StudyGraphics

#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

May 30, 2025
#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis
StudyGraphics

#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis

April 21, 2025
Next Post
Criminal behavior more associated with frontotemporal dementia than Alzheimer disease

Criminal behavior more associated with frontotemporal dementia than Alzheimer disease

Whole grain consumption associated with decreased all-cause, cardiovascular mortality

Whole grain consumption associated with decreased all-cause, cardiovascular mortality

Standardized measures effectively tracked psoriasis and acne outcomes

Standardized measures effectively tracked psoriasis and acne outcomes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Volumetric diet and time-restricted eating demonstrate similar outcomes for weight reduction
  • Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss
  • Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.